CJC-1295 and Tesamorelin Together: What Is Known
CJC-1295 and Tesamorelin taken together: what each one is, how each is regulated, and what is known about combining them.
Timing, interactions and safety
Evidence for the combination
No studies tested these together (PubMed search: 15 results, 2 Oct 2026).
Side by side
Showing 7 of 13 fields where the two differ. Class, Category, PCAC vote, Jul 2026, WADA, Anti-doping detection, Evidence strength are the same or both unknown.
| Field | CJC-1295 | Tesamorelin |
|---|---|---|
| Class | GHRH analog | GHRH analog |
| Also called | CJC, mod GRF, GRF 1-29 | tesa, Egrifta |
| Category | Growth hormone | Growth hormone |
| FDA status | Not FDA approved · research chemical | FDA approved (Egrifta) |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S2.2.4)CJC-1295 is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. | Prohibited by WADA (S2.2.4)Tesamorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. Tesamorelin is also an FDA-approved medicine; an athlete would need a therapeutic use exemption. |
| Anti-doping detection |
|
|
| Half-life | No published half-life foundPubMed search, 11 Oct 2026 | 11 minutessubcutaneous (EGRIFTA WR 1.28 mg) · FDA label (Egrifta WR) |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: The Journal of clinical endocrinology and metabolism 2006, PMID 16352683 | Human RCT evidence, 4 of 4Strongest: eNeurologicalSci 2026, PMID 42382101 |
| Human studies we summarised | 4 human (1 randomized or controlled) of 7 summarised | 12 human (11 randomized or controlled) of 16 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 2 mg, 5 mg, 10 mg | 2 mg, 5 mg, 10 mg, 20 mg |
| Named in FDA warning letters, 2026 | Not in the letters we track | Yes (24 Aug 2026) |
CJC-1295 vs Tesamorelin
Choosing between the two rather than combining them? The comparison lines them up field by field.
Both are GHRH analogues, built for very different durations
After a single injection in healthy adults, the estimated half-life of CJC-1295 was 5.8-8.1 days.[5]
The CJC-1295 used in trials binds permanently to albumin after injection.[6]
Tesamorelin's label gives a half-life of 11 minutes in healthy subjects after a single injection of the WR formulation.[10]
Converted to a common unit, CJC-1295's reported half-life is about 760 to 1060 times tesamorelin's.
Calculated from cjc half life days 5.8, 8.1; tesamorelin half life minutes 11. Formula: CJC hours = days x 24 = 139.2 to 194.4 h; tesamorelin hours = 11 / 60 = 0.183 h; ratio = 139.2 / 0.183 = 759 and 194.4 / 0.183 = 1060
What each shows in people
In healthy adults, a single CJC-1295 injection raised mean growth hormone 2- to 10-fold for 6 days or more, and IGF-I 1.5- to 3-fold.[5]
A trial randomised 412 patients with HIV and abdominal fat to daily tesamorelin or placebo for 26 weeks, with visceral fat on CT as the primary endpoint.[15]
In a pulsatility study, CJC-1295 raised trough GH 7.5-fold and IGF-I 45%.[6]
FDA, label and sport status
FDA says it has identified serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction.[17]
Tesamorelin's label warns that it raises IGF-1 and says the effects of prolonged elevation are unknown.[10]
WADA lists both in the same prohibited GHRH class.[2]
A PubMed search on 2 Oct 2026 for CJC-1295 together with tesamorelin matched 15 records; none is recorded as a trial of the two combined.
Calculated from pubmed query ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab]); records matched 15; search date 2026-10-02. Formula: records_matched = PubMed count recorded in combinations.json for the query on search_date
Common questions
CJC-1295 vs tesamorelin: what is the difference?
Tesamorelin's label gives a half-life of minutes, while the estimated half-life of CJC-1295 in healthy adults was 5.8-8.1 days.[5]
Can you take CJC-1295 and tesamorelin together?
No trial in the cached results has combined them. WADA lists both under the same GHRH class.[2]
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 3An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
- 4Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
- 5Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
- 6Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.The Journal of clinical endocrinology and metabolism · 2006PMID 17018654Accessed 2 Oct 2026
- 7Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.American journal of physiology. Endocrinology and metabolism · 2006PMID 16822960Accessed 2 Oct 2026
- 8PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) (33 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10EGRIFTA WR (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]FDA label (Egrifta WR), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 11The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026
- 12Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV · 2019PMID 31611038Accessed 2 Oct 2026
- 13The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.The Journal of frailty & aging · 2019PMID 31237318Accessed 2 Oct 2026
- 14PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026
- 16PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 17Official web pageOfficial web page · web page
Found an error? Report a correction.